Search fresh public links, source activity, and ready-to-use post angles for Glp-1.
Fresh curated links around GLP-1 are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
A once-daily GLP-1 receptor agonist decreased events of level 2 and level 3 hypoglycemia for adults after Roux-en-Y gastric bypass, according to topline results from a phase 3 tria...
Based on Danish data, the study found those on GLP-1s had 17% less long-term absences.
Based on Danish data, the study found those on GLP-1s had 17% less long-term absences.
Based on Danish data, the study found those on GLP-1s had 17% less long-term absences.
The benefits of GLP-1s keep adding up.
The benefits of GLP-1s keep adding up.
The higher-dosage GLP-1 agonists largely engendered greater cardiometabolic improvements.
The higher-dosage GLP-1 agonists largely engendered greater cardiometabolic improvements.
Sales of Mounjaro, Eli Lilly’s diabetes drug, rose 91 per cent in the second quarter of the year to US$9.94 billion, well above analysts' expectations.
IFF has released new research examining how GLP 1 use is influencing food behaviours among Indian consumers and what those shifts may mean for the future of food and beverage innov...
For a lot of older adults, especially those carrying real cardiovascular or metabolic risk, GLP-1s may offer benefits beyond the number on the scale when under a doctor's supervisi...
New research examines the emerging benefits and unanswered questions surrounding this rapidly expanding class of medications. Millions of people are now using GLP-1 receptor agonis...
Most of the supplement industry's GLP-1 content covers two moments: the drug itself, and what happens after someone stops taking it. NNB Nutrition's Post GLP-1 Window framework bel...
Bacteria engineered to sense and reduce glucose levels could be the future of type 2 diabetes treatments, following pre-clinical trials on animal models.Continue ReadingCategory:
A new study establishes that GLP-1 receptor agonists significantly reduce core behavioral markers of Binge Eating Disorder, including active binge episodes, loss-of-control eating,...
There is little debate over which Wall Street profit story is the biggest of the moment: artificial intelligence. For second-biggest, consider the case for GLP-1 drugs.
GLP-1 drugs, originally developed to treat diabetes and now widely used for obesity, are reshaping healthcare in the US.
You love the idea of GLP-1s like Ozempic—getting to accomplish your weight-loss goals and reap surprising bonus benefits you’ve heard about, like a lower Alzheimer’s disease risk a...
GLP-1 wins again.ScienceAlert stories are written, fact-checked, and edited by humans, never generated by AI. Don't miss a story, subscribe here.
Finally, Some Evidence Employers Can Use to Justify Covering GLP-1s Anonymous (not verified) Thu, 08/27/2026 - 09:40 pharmagather item url Finally, Some Ev...
A new research report reveals GLP-1 adoption isn't static, men are an overlooked demographic and usage varies dramatically by restaurant — challenging chains to rethink what they t...
Researchers engineered a probiotic to sense glucose spikes and release GLP-1 on demand. It worked in diabetic mice and monkeys, but human trials remain ahead.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.